达罗他胺联合雄激素剥夺治疗和多西他赛治疗转移性激素敏感性前列腺癌按疾病体积和风险分组的III期ARASENS试验
ARASENS试验中,转移性激素敏感性前列腺癌患者随机接受达罗他胺或安慰剂联合雄激素剥夺治疗和多西他赛。在高体积、高风险和低风险亚组中,达罗他胺均提高总生存期,不良事件谱与总体人群一致。
要点
- 达罗他胺提高高体积疾病患者总生存期(HR 0.69;95%CI 0.57-0.82)。
- 达罗他胺提高高风险疾病患者总生存期(HR 0.71;95%CI 0.58-0.86)。
- 达罗他胺提高低风险疾病患者总生存期(HR 0.62;95%CI 0.42-0.90)。
核心结论
- 在高体积和高风险/低风险转移性激素敏感性前列腺癌患者中,达罗他胺联合雄激素剥夺治疗和多西他赛强化治疗提高总生存期,亚组不良事件谱相似,与总体人群一致。
研究设计与样本
- ARASENS是一项III期随机对照试验,转移性激素敏感性前列腺癌患者随机接受达罗他胺或安慰剂联合雄激素剥夺治疗和多西他赛。
- 共纳入1305例患者,其中1005例(77%)为高体积疾病,912例(70%)为高风险疾病。
- 高体积疾病定义为内脏转移和/或≥4处骨转移且至少1处位于脊柱/骨盆之外;高风险疾病定义为≥2个风险因素:Gleason评分≥8、≥3处骨病灶、存在可测量内脏转移。
主要发现
- 达罗他胺较高体积疾病患者总生存期优于安慰剂(HR 0.69;95%CI 0.57-0.82)。
- 达罗他胺较高风险疾病患者总生存期优于安慰剂(HR 0.71;95%CI 0.58-0.86)。
- 达罗他胺较低风险疾病患者总生存期优于安慰剂(HR 0.62;95%CI 0.42-0.90)。
- 在较小的低体积亚组中,达罗他胺也提示生存获益(HR 0.68;95%CI 0.41-1.13)。
- 在所有疾病体积和风险亚组中,达罗他胺较安慰剂改善至去势抵抗性前列腺癌时间和至后续全身抗肿瘤治疗时间等临床相关次要终点。
关键数值与推荐
- 高体积亚组3级或4级不良事件发生率:达罗他胺组64.9% vs 安慰剂组64.2%。
- 低体积亚组3级或4级不良事件发生率:达罗他胺组70.1% vs 安慰剂组61.1%。
- 各亚组治疗组间不良事件相似,常见不良事件中许多为多西他赛已知毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For patients with metastatic hormone-sensitive prostate cancer, metastatic burden affects outcome. We examined efficacy and safety from the ARASENS trial for subgroups by disease volume and risk. METHODS: Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to darolutamide or placebo plus androgen-deprivation therapy and docetaxel. High-volume disease was defined as visceral metastases and/or ≥ 4 bone metastases with ≥ 1 beyond the vertebral column/pelvis. High-risk disease was defined as ≥ 2 risk factors: Gleason score ≥ 8, ≥ 3 bone lesions, and presence of measurable visceral metastases. RESULTS: Of 1,305 patients, 1,005 (77%) had high-volume disease and 912 (70%) had high-risk disease. Darolutamide increased overall survival (OS) versus placebo in patients with high-volume (hazard ratio [HR], 0.69; 95% CI, 0.57 to 0.82), high-risk (HR, 0.71; 95% CI, 0.58 to 0.86), and low-risk disease (HR, 0.62; 95% CI, 0.42 to 0.90), and in the smaller low-volume subgroup, the results were also suggestive of survival benefit (HR, 0.68; 95% CI, 0.41 to 1.13). Darolutamide improved clinically relevant secondary end points of time to castration-resistant prostate cancer and subsequent systemic antineoplastic therapy versus placebo in all disease volume and risk subgroups. Adverse events (AEs) were similar between treatment groups across subgroups. Grade 3 or 4 AEs occurred in 64.9% of darolutamide patients versus 64.2% of placebo patients in the high-volume subgroup and 70.1% versus 61.1% in the low-volume subgroup. Among the most common AEs, many were known toxicities related to docetaxel. CONCLUSION: In patients with high-volume and high-risk/low-risk metastatic hormone-sensitive prostate cancer, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS with a similar AE profile in the subgroups, consistent with the overall population.[Media: see text].
引用
- Hussain M, Tombal B, Saad F, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023. PMID: 36795843. doi:10.1200/JCO.23.00041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。